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Medical Sciences 
Expression of biologically active human corticosteroid binding 
globulin by insect cells: Acquisition of function requires 
glycosylation and transport 
(baculovirus-mediated expression/in vitro translation/protein folding) 
JAYASRI GHOSE-DASTIDAR*, J. B. ALEXANDER Ross*, AND REZA GREENt 
Departments of *Biochemistry and tPhysiology and Biophysics, Mount Sinai School of Medicine, New York, NY 10029 
Communicated by Edwin D. Kilbourne, April 22, 1991 
ABSTRACT Human corticosteroid binding globulin 
(hCBG) is a 50- to 55-kDa serum glycoprotein that binds 
cortisol and progesterone with high affinity. To map the 
steroid-binding domain and to investigate the folding pathways 
of hCBG, we have established an expression system based on 
infection of insect cells with a recombinant baculovirus encod- 
ing hCBG. Infected Spodoptera frugiperda (Sf9) cells secrete 
immunoreactive hCBG at high levels (16-24 pmol per 106 cells 
per 40 h), and the recombinant protein binds cortisol with an 
affinity and specificity equivalent to that of human serum- 
derived hCBG. Thus, this system has the potential to provide 
large amounts of wild-type and mutant hCBGs for physical- 
chemical analysis. Cotranslational asparagine-linked glycosyl- 
ation is essential for acquisition of steroid-binding capability, as 
shown by the lack of cortisol-binding activity of unglycosylated 
hCBG secreted in the presence of tunicamycin. Golgi- 
associated oligosaccharide processing, however, is not required 
for activity, as demonstrated by the endoglycosidase H suscep- 
tibility of the fully active, secreted glycoprotein. Comparison of 
the steroid-binding properties of intracellular and secreted 
hCBG with that synthesized in vitro in the rabbit reticulocyte 
lysate system suggests that this protein undergoes a maturation 
process during transport hrough the secretory pathway. This 
system will be useful for identifying the molecular determinants 
of biological function in hCBG. 
The steroid-binding lobulins are excellent model systems for 
studying how protein structure and conformational dynamics 
determine function. The diverse biological activities pro- 
posed for these serum proteins suggest that they contain 
multiple functional domains. Their high-affinity ligand bind- 
ing provides a sensitive indicator of proper tertiary structure, 
facilitating the analysis of protein folding in vivo and in vitro. 
Furthermore, the postsynthetic transport of these glycopro- 
teins through endoplasmic reticulum (ER) and Golgi com- 
partments raises the possibility of identifying intracellular 
folding intermediates. To incorporate biophysical and cell 
biological approaches, we have established a system for 
high-level expression of human corticosteroid binding glob- 
ulin (hCBG), and we report here our first correlations of 
structure and function in this polypeptide. 
In humans, 80-90% of the cortisol present in serum is 
bound with high affinity and specificity to hCBG (1, 2). hCBG 
is an acidic glycoprotein synthesized primarily in liver and 
kidney, and it is secreted into the circulation as a 50- to 
55-kDa monomer containing a single steroid-binding site (2). 
Its cDNA sequence predicts a 405-amino acid protein, which 
includes a 22-residue amino-terminal signal peptide and six 
consensus sites for asparagine-linked glycosylation; overall, 
hCBG shares significant homology with members of the 
The publication costs of this article were defrayed in part by page charge 
payment. This article must therefore be hereby marked "advertisement" 
in accordance with 18 U.S.C. ?1734 solely to indicate this fact. 
serpin (serine protease inhibitor) family of protease inhibitors 
(3). 
A generally accepted function of hCBG is the maintenance 
of an appropriate balance of free and protein-bound cortisol 
in serum (1, 2, 4, 5). It has recently been proposed that release 
of cortisol from hCBG following proteolytic leavage by 
neutrophil-derived elastase provides a mechanism to target 
cortisol to sites of inflammation (6, 7). The observation of 
high-affinity cell-surface binding sites for hCBG (8, 9) sug- 
gests an additional role in cortisol delivery and uptake, or, 
alternatively, in a cortisol-regulated signal transduction path- 
way (10). To reconcile and understand these possible modes 
of action of hCBG will require the identification fsteroid- 
and receptor-binding domains within this polypeptide and the 
delineation of specific features that regulate steroid binding 
and release. 
At present we have limited knowledge of the structure of 
the steroid-binding site of hCBG, since a crystallographic 
description of this protein has not yet been achieved. The 
interaction of hCBG with cortisol protects one of its two 
cysteine residues from chemical modification (11) and also 
quenches the fluorescence of one or more of its four tryp- 
tophans (12). Notably, Cys-228 and the four tryptophans are 
conserved between human, rat, and rabbit CBG sequences 
(3, 13, 14), suggesting that they have functional significance; 
there have been no reports, however, of site-directed mutants 
in which steroid binding is altered. 
To investigate how hCBG acquires steroid-binding activ- 
ity, we have expressed the wild-type protein in vitro, in the 
reticulocyte lysate system, and in vivo, in insect cells infected 
with an hCBG recombinant baculovirus (15). Here we com- 
pare the properties of recombinant hCBG with those of native 
hCBG purified from human serum. We report hat insect cells 
secrete high levels of hCBG that is fully active in cortisol 
binding. To our knowledge, this is the first demonstration 
that the cDNA identified by Hammond et al. (3) encodes 
authentic, functional hCBG. Using this system, we have 
determined that acquisition of binding activity requires core 
glycosylation i  the ER and may also involve subsequent 
maturation steps. 
METHODS 
Cloning of CBG cDNA. CBG cDNA was isolated from a
human liver cDNA library that had been cloned into the 
EcoRI site of Agtll phage DNA (Clontech). Plaques contain- 
ing CBG cDNA were identified by hybridization fimmobi- 
lized phage to 32P-labeled synthetic oligonucleotide probes 
derived from 5' and 3' regions of the hCBG cDNA sequence 
Abbreviations: hCBG, human corticosteroid binding lobulin; ER, 
endoplasmic reticulum; S+-, S--, and GP-hCBG, signal peptide- 
containing, signal peptide-cleaved, and glycosylated forms of hCBG, 
respectively. 
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(4). The 5' probe corresponded to nucleotides 25-49 (5'- 
TATACTGGACAATGCCACTCCTCCT-3'), and the 3' 
probe corresponded to nucleotides 1371-1395 (5'-CAGACT- 
TGTGTCTAACTTTAGGCAT-3'). Phage DNA was purified 
from plaques to which both probes hybridized. One isolate 
contained a 1.4-kilobase EcoRI insert whose restriction map 
was that predicted for full-length hCBG cDNA, and partial 
DNA sequencing confirmed the presence of the initiator ATG 
codon and 35 base pairs of 5' sequence (4). This insert was 
amplified by cloning into EcoRI-digested pGEM1 (Promega), 
producing pG-CBG1, which served as a vector for in vitro 
transcription reactions (see below). The EcoRI insert was 
then cloned into the unique EcoRI site of the baculovirus- 
derived pVL-1393 vector (Invitrogen), placing hCBG expres- 
sion under control of the baculovirus polyhedrin promoter. 
This recombinant plasmid was designated pVL-CBG1. 
In Vitro Transcription a d Translation. CBG mRNA was 
synthesized invitro using pG-CBG1 as template and T7 RNA 
polymerase, according to the manufacturer's protocols 
(Promega). The resulting mRNA was used to program cell- 
free protein synthesis n the rabbit reticulocyte lysate system 
(Promega); where indicated, reaction mixtures were supple- 
mented with canine pancreatic microsomes prepared by the 
method of Shields and Blobel (16). 
Production of Recombinant Baculovirus. A stock of recom- 
binant baculovirus was produced by the method of Summer 
and Smith (15) using pVL-CBG1 DNA and AcMNPV (bac- 
ulovirus) DNA for the mixed transfection of Spodoptera 
frugiperda (Sf9) cells. Recombinant baculoviruses were iden- 
tified by hybridization with 32P-labeled hCBG cDNA and 
purified by visual screening of plaque morphology (15). Viral 
titers were determined by plaque assay in Sf9 cells. 
Infection and Metabolic Labeling. For expression of hCBG, 
Sf9 cells were infected with recombinant virus at a multiplic- 
ity of 10-25 plaque-forming units per cell. For radiolabeling, 
cells were incubated with medium lacking unlabeled methio- 
nine and containing [35S]methionine at 100 ACi/ml (specific 
activity = 800 Ci/mmol; 1 Ci = 37 GBq; Amersham). Cells 
were harvested in phosphate-buffered saline and lysed using 
phosphate-buffered saline containing 0.5% (wt/vol) sodium 
deoxycholate and 0.5% (vol/vol) Nonidet P-40; postnuclear 
supernatants were recovered after centrifugation i  a Mi- 
crofuge. 
Immunoprecipitation and Glycosidase Treatment. For im- 
munoprecipitation, we used a rabbit antiserum raised against 
hCBG that had been purified from human serum. (Both the 
antiserum and purified hCBG were kind gifts of R. Kuhn of 
Hana Biologics.) Five microliters of this antiserum quanti- 
tatively immunoprecipitates hCBG from 2 x 106 infected Sf9 
cells. Immunoprecipitation wascarried out as described (17). 
To remove asparagine-linked carbohydrates, immunoreac- 
tive products were digested with endoglycosidase H or 
N-Glycanase according to manufacturer's protocols (Gen- 
zyme). Radiolabeled proteins were resolved in 12.5% acry- 
lamide/SDS gels, which were then subjected to fluorography 
and exposed to Kodak XAR film at -70?C. Quantitation was 
by densitometric s anning of the fluorograms. 
[3H]Cortisol Binding Assay. Scatchard analysis and satu- 
ration binding measurements were made using [3H]cortisol 
(40-50 Ci/mmol; New England Nuclear) in the filter assay 
described by Schiller and Petra (18). Equilibrium association 
constants were determined by competition with unlabeled 
steroids (19). Sf9 cell lysates, human serum, and purified 
hCBG derived from human serum were assayed directly after 
dilution in 10 mM Tris HCI at pH 7.4. Media samples were 
concentrated and dialyzed against the same buffer. 
RESULTS 
In Vitro Synthesis and Modification ofRecombinant hCBG. 
A full-length hCBG cDNA was isolated from a human liver 
cDNA library, using hybridization probes derived from the 
hCBG cDNA sequence reported by Hammond et al. (3). 
mRNA transcribed in vitro from this cDNA was used to 
program protein synthesis in the reticulocyte lysate-derived 
system, and the [35S]methionine-labeled products were sub- 
jected to immunoprecipitation with anti-hCBG antibodies. 
The primary translation product is an immunoreactive 42- 
kDa polypeptide (S+; Fig. 1A, lane 1). Addition of canine 
pancreatic microsomes causes the appearance of several 
higher molecular mass forms of 43-50 kDa (GP; Fig. 1A, lane 
2). These forms are not digested by exogenously added 
protease (Fig. 1A, lanes 3 and 4), indicating that they are 
localized within the lumen of the microsomal vesicles. Re- 
moval of asparagine-linked carbohydrates by treatment with 
endoglycosidase H converts these larger forms to a 39-kDa 
species, indicating cleavage of the amino-terminal signal 
peptide (S-; Fig. 1A, lane 5). The in vitro protein product of 
this cDNA thus displays the molecular mass, immunoreac- 
A 1 2 3 4 5 
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FIG. 1. Expression of recombinant hCBG in vitro and in vivo. 
[35S]Methionine-labeled hCBG derived from cell-free translation (A) 
or Sf9 cells (B) was immunoprecipitated with anti-hCBG antiserum 
and resolved on SDS/12% PAGE. (A) In vitro-transcribed hCBG 
mRNA was translated in a reticulocyte lysate-derived system in the 
absence (lane 1) or presence (lanes 2-5) of canine pancreatic mi- 
crosomes (mb). After translation, the reactions were incubated with 
trypsin (100 ,utg/ml, 30 mmn 0?C) in the presence (lane 3) or absence 
(lane 4) of 0.5% (vol/vol) Triton X-100. Lane 5, the immunoprecip- 
itate was incubated with endoglycosidase H (Endo H) prior to 
electrophoresis. (B) Sf9 cells infected with a baculovirus encoding 
hCBG (lanes 1-3 and 5) or a wild-type baculovirus (lane 4) were 
metabolically abeled with [35S]methionine for 2 h at 66 h postinfec- 
tion, and cell Iysates (lanes 1-4) or medium (med; lane 5) were 
subjected to immunoprecipitation. The immunoprecipitates shown in 
lane 1 were treated with endoglycosidase H (+ E/H- lane 2) or 
N-Glycanase (+N/G; lane 3) prior to electrophoresis. UP, S and 
S- refer to glycosylated hCBG, signal-containing pre-hCBG, and 
signal-cleaved unglycosylated hCBG, respectively. In B, the in vitro 
products were electrophoresed inan adjacent lane (not shown), and 
we consistently observe comigration ofthe respective in vitro and in 
vivo forms. Positions of molecular mass standards (in kDa) are 
indicated. 
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tivity, cotranslational targeting, and covalent modifications 
predicted for hCBG. 
Synthesis and Secretion of hCBG by Insect Cells. hCBG 
cDNA was incorporated into a recombinant baculovirus o 
that its expression would be driven by the strong viral 
polyhedrin promoter. The recombinant virus was used to 
infect Sf9 cells at a multiplicity of 25 plaque-forming units per 
cell, and hCBG synthesis was monitored by radiolabeling and 
immunoprecipitation (Fig. 1B). During a 2-h pulse with 
[35S]methionine, a high level of hCBG-immunoreactive ma- 
terial was synthesized, corresponding to 2-5% of the total 
cellular protein synthesis (Fig. 1B, lane 1). All of the molec- 
ular forms identified by in vitro translation are detected in 
infected cell lysates. Typically, we observe 50-75% of the 
total hCBG immunoreactivity n the higher molecular mass 
glycosylated forms of hCBG (GP), which are substrates for 
endoglycosidase H and N-Glycanase (Fig. 1B, lanes 2 and 3). 
A small amount of the signal peptide-cleaved form of hCBG 
(S-) is synthesized, and the remainder is represented in the 
signal peptide-containing form of hCBG (S+). In the secreted 
fraction, the glycosylated forms predominate (Fig. 1B, lane 5; 
Fig. 4A, lane 3), and these polypeptides are susceptible to 
endoglycosidase H digestion (data not shown). GP-hCBG is 
secreted with a ti/2 of 90 min; at the end of a 5-h chase, -60% 
of the total GP-hCBG is extracellular, and this material is 
relatively stable (Fig. 2). 
The intracellular level of S+-hCBG varies among experi- 
ments, and its behavior is distinct from that of GP-hCBG. The 
pulse-labeled S+-hCBG species rapidly appears in the me- 
dium and is subsequently degraded (Fig. 2). These data are 
consistent with inefficient translocation i to the ER lumen or, 
alternatively, with inefficient signal peptide cleavage follow- 
ing translocation. In either case, the unglycosylated precur- 
sor could be susceptible to cellular proteases, and its appar- 
ent secretion might be secondary to cell damage caused by 
viral infection. For our purposes, the relative lability of 
S+-hCBG after externalization supports the use of culture 
medium as a source of GP-hCBG for purification a d anal- 
ysis. 
A competitive immunoassay was used to quantify hCBG 
production. The displacement curve of Sf9-derived material 
is parallel to that of hCBG purified from human serum, 
indicating a high degree of similarity in antigenic determi- 
nants (Fig. 3). To measure secretion, infected cultures were 
fed with fresh medium at 48 h postinfection, and cells and 
2.5 
inside outside 
1.0 _ 
>0.8 _ 
C: 0.6 - 
0.4 --, 
0.2 -NiN. 
0 
1 2 3 4 5 1 2 3 4 5 
time of chase (h) 
FIG. 2. Kinetics of secretion of recombinant hCBG from Sf9 
cells. Sf9 cells infected with a recombinant baculovirus encoding 
hCBG were pulse-labeled for 1 h with [35S]methionine at 100 ,uCi/ml 
and chased in the presence of 10 mM unlabeled methionine. hCBG 
was immunoprecipitated from cell lysates and media, resolved on 
SD)S/PAGE, and quantified bydensitometry. Thevalues hown for 
intracellular (inside) and medium (outside) hCBG are derived from 
equal numbers of cells, allowing them to be directly compared. u,
GP-hCBG; *, S+-hCBG. 
hCBG (ng) 
5 15 30 50 150 300 500 
100 - 
80- 
0 
n 60- 
0 
8 40 -\ 
C \ 
" 20 
\ 
0.2 0.6 1.2 2 6 12 20 
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FIG. 3. Immunoquantitation of hCBG production. [35S]Methio- 
nine-labeled translation products (1 x 105 cpm; as in Fig. 1, lane 1) 
were incubated with sufficient polyclonal anti-hCBG antiserum to 
achieve 50% immunoprecipitation, n the presence of the indicated 
amounts of purified human serum hCBG (e), human serum (A), and 
Sf9 cell lysate (o). The immunoprecipitates w re resolved on SDS/ 
PAGE, and the amount of radiolabeled hCBG recovered in antigen- 
antibody complexes was quantified by densitometry. 
media were harvested at 90 h. Under these conditions, 106 
infected cells contain 2.3-3 Ag (58-75 pmol) of immunore- 
active hCBG, and media derived from 106 cells contain 1 ,sg 
(25 pmol) of hCBG (Table 1); this corresponds to the secre- 
tion of -1-2 ,ug per ml per 24 h in monolayer culture. 
Biological Activity of Recombinant hCBG. The steroid- 
binding properties of hCBG derived from Sf9 cells and human 
serum were compared.by using saturation binding and Scatch- 
ard analyses (18, 19). The determination of active hCBG in 
human serum by saturation binding of [3H]cortisol correlates 
well with the amount measured by immunoassay (Table 1). 
While uninfected Sf9 cells have negligible [3H]cortisol- 
binding activity (data not shown), infected cultures contain 
10-25 pmol per 106 cells. The secreted fraction contains 
75-90% of the total activity, and this material binds 0.7-0.8 
mol of cortisol per mol of immunoreactive hCBG (Table 1). 
Most importantly, the affinity of the secreted recombinant 
protein for cortisol is indistinguishable from that of serum 
hCBG, as is the rank order of binding of other steroids (Table 
2). These data indicate that Sf9 cells secrete authentic hCBG 
that contains a native steroid-binding site. 
We also tested the steroid-binding capability of in vitro- 
synthesized hCBGs. Reticulocyte lysates programmed with 
hCBG mRNA contain 2-5 ng of hCBG per 100-dl reaction 
mixture; if fully active, this material would bind 40-100 fmol 
of [3H]cortisol, which is readily detectable in our assay (see 
legend to Table 1). Neither the primary in vitro translation 
product (Fig. 1A, S+) nor the mixture of the S+-hCBG and 
Table 1. Production of recombinant hCBG 
Parameter Human serum Sf9 lysate Sf9 medium 
IR hCBG, pmol 50 113 60 
[3H]Cortisol, pmol 54 6 48 
RBA 1.08 0.05 0.80 
Values are for 100 ,ul of human pregnancy serum and for lysate and 
medium fractions derived from 2.5 x 106 Sf9 cells. Immunoreactive 
(IR) hCBG was quantified as described in the legend to Fig. 3. 
Saturation binding of [3H]cortisol was measured as described in 
Methods. In 50-,ul reaction mixtures, binding islinear between 25 and 
250 fmol of hCBG, and the standard error is ?+16%. The relative 
binding activity (RBA) is the ratio of [3H]cortisol to immunoreactive 
hCBG. 
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Table 2. Comparison of steroid binding by recombinant and 
serum hCBG 
Human serum Sf9 cells 
Ka Ka 
Steroid Ka, M-1 Ka(CS) Ka, M-1 Ka(Cs) 
Cortisol 2.6 x 108 1.0 1.8 x 108 1.0 
Progesterone 4.3 x 107 0.17 2.2 x 107 0.12 
Testosterone 1.8 x 106 0.007 1.0 x 106 0.006 
Dexamethasone 5.5 x 104 0.0002 2.6 x 104 0.0001 
Ecdysone <1.4 x 104 <1.4 x 104 
The association constants for cortisol binding to hCBG in human 
pregnancy serum and Sf9 cell medium were determined by Scatchard 
analysis (19, 20). Association constants for the other steroids were 
determined by their competition with [3H]cortisol at50% saturation 
of binding. The error in the association constants is a factor of 2. 
Ka(CS), Ka of cortisol. 
GP-hCBG forms generated by inclusion of microsomes (Fig. 
1A, lane 2) exhibited detectable cortisol-binding activity. 
Effect of Glycosylation on Steroid-Binding Activity. To 
examine the role of glycosylation in the production of active 
hCBG, infected Sf9 cells were treated with tunicamycin, 
which inhibits asparagine-linked glycosylation. Metabolic 
labeling revealed the synthesis of both S+- and S--hCBG 
(Fig. 4A, lane 2). As previously observed in hepatoma cells 
(20), unglycosylated hCBG is secreted at reduced levels 
relative to GP-hCBG (Fig. 4A, lanes 3 and 4). Longer 
autoradiographic exposures also indicated residual synthesis 
of GP-hCBG in tunicamycin-treated cells, and this was 
confirmed by immunoblot analysis of unlabeled medium from 
parallel cultures (Fig. 4B, lane 2). To separate S+- and 
S--hCBG from the glycosylated forms, this material was 
adsorbed to concanavalin A-Sepharose (Fig. 4B, lane 3). 
Saturation binding of [3H]cortisol to secreted hCBG was 
reduced to 24% of the control value by tunicamycin treat- 
A B 
1 2 3 4 1 2 3 
W _ -GP- 3 
TM - + - + + + 
3H-Cs 850 200 0 
(fmol) 
FIG. 4. Role of glycosylation i secretion of biologically active 
hCBG. Infected Sf9 cells were treated with or without unicamycin 
(5 ,ug/ml) for 5 h at 40 h postinfection. Inparallel cultures, media 
were then replaced with either methionine-free m dium containing 
[35S]methionine at 100 ,uCi/ml (A) or complete medium (B), lacking 
or containing tunicamycin (TM). In both cases, incubation was 
continued for an additional 16 h. (A) Labeled cells (lanes 1 and 2) and 
media (lanes 3 and 4) were harvested and subjected to immunopre- 
cipitation with anti-hCBG antibodies, and the immunoprecipitates 
were resolved by SDS/PAGE. (B) Unlabeled culture media were 
harvested, concentrated, and incubated with concanavalin A-Seph- 
arose to adsorb glycosylated polypeptides as described (21). The 
starting material ( anes 1 and 2) and the material that did not bind to 
concanavalin A (lane 3) were resolved by SDS/PAGE and identified 
by immunoblotting (22). Saturation binding of [3H]cortisol, measured 
in the same amount of material as was loaded on the gel, is indicated 
below the corresponding lanes (3H-Cs). 
ment, and concanavalin A-purified unglycosylated hCBG 
was completely inactive (Fig. 4B). 
DISCUSSION 
We report he production of high levels of biologically active 
hCBG in a heterologous system. Sf9 cells infected with an 
hCBG recombinant baculovirus ecrete large quantities of 
glycosylated hCBG (16-24 pmol per 106 cells per 40 h); this 
level is similar to that observed in other baculovirus-directed 
expression systems (23). The secreted protein is functionally 
equivalent o human serum hCBG in its relative steroid- 
binding activity, high affinity for cortisol, and rank order of 
binding of other steroids. Large-scale production of wild-type 
and mutant hCBG for physical-chemical analysis and struc- 
ture-function studies is therefore feasible using the baculo- 
virus system. 
Comparison of the steroid-binding properties of different 
molecular forms of hCBG provides a preliminary picture of 
how this protein acquires its native structure during biogen- 
esis. The primary in vitro translation product does not bind 
cortisol, suggesting that signal peptide cleavage and/or core 
glycosylation are required for biological activity. A specific 
requirement for glycosylation is indicated by the observation 
that unglycosylated hCBG synthesized in the presence of 
tunicamycin, which consists of a mixture of signal-containing 
and signal-cleaved forms, does not bind cortisol. Subsequent 
addition of terminal sugars, however, which normally ac- 
companies Golgi transport of hCBG in hepatocytes, isclearly 
not required for function, as shown by the endoglycosidase 
H sensitivity of the fully active, secreted glycoprotein. In 
previous tudies, treatment of serum-derived native hCBG 
with a mixture of glycosidases, which effectively removed 
>90% of the bound sugar residues, did not significantly 
reduce cortisol binding (24). Our data support he conclusion 
that the complex carbohydrate moieties of hCBG are not 
directly involved in steroid binding. Instead, we have iden- 
tified glycosylation as a critical cotranslational event that 
most likely influences the subsequent folding pathway(s) of 
hCBG within the ER lumen. 
Several observations further suggest hat hCBG does not 
achieve its final tertiary structure immediately upon arrival in 
the ER. In vitro, hCBG synthesized in the presence of 
microsomes does not bind cortisol, despite having undergone 
membrane translocation a d early covalent modifications. A 
more striking observation is that in Sf9 cells the relative 
cortisol-binding activity of cell-associated hCBG is much 
lower than that of secreted hCBG, even after taking into 
account the presence of inactive unglycosylated polypep- 
tides. That is, hCBG polypeptides in a typical Sf9 cell lysate 
preparation are 50-75% glycosylated (Fig. 1B, lane 1; Fig. 
4A, lane 1) but exhibit only 7-10% of the native cortisol- 
binding capacity per mole of immunoreactive hCBG (Table 
1). In contrast, the extracellular material is >90% glycosyl- 
ated (Fig. 1B, lane 5; Fig. 4A, lane 3) and binds cortisol 
70-80% as efficiently as serum-derived hCBG. A trivial 
explanation is that the cell lysate contains immunoreactive 
degradation products, not present in the extracellular me- 
dium, which have lost cortisol-binding activity. This seems 
unlikely, however, since there is a good correlation between 
hCBG measured by immunoassay and intact hCBG polypep- 
tides detected by SDS/PAGE. We hypothesize that newly 
synthesized glycosylated molecules acquire full steroid- 
binding capability posttranslationally, and, once they have 
achieved a native structure, they are rapidly secreted. The 
high yield of active hCBG in the extracellular medium can 
then be explained by time-dependent conversion of inactive 
intracellular polypeptides to active extracellular ones. 
The nature of this maturation process remains to be 
investigated. Attention has focused on the ER lumen as the 
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site of folding and assembly, and genetic and biochemical 
evidence has implicated accessory proteins, termed chaper- 
onins, in folding and proofreading phenomena (25). Many of 
the documented examples involve oligomerization of integral 
membrane proteins and assembly of multimeric secretory 
complexes (25); in the case of hCBG, an analogous intramo- 
lecular folding process may occur. We suggest that formation 
or stabilization of a native steroid-binding site could require 
interaction with chaperonins. There are several candidates 
for such proteins in Sf9 cells (26). In this regard, an analogy 
may be made between hCBG and the intracellular glucocor- 
ticoid receptor (GR), which binds to a cytosolic heat shock 
protein, hsp90, soon after synthesis; recent evidence sug- 
gests that this association occurs via the GR steroid-binding 
domain (27, 28). Although GR and hCBG do not have 
identical steroid specificities (29), suggesting differences in 
their steroid-binding sites, the two proteins could share a 
common requirement to sequester and stabilize an unoccu- 
pied steroid-binding pocket after synthesis. In the case of 
hCBG, we speculate that interaction with ER components, 
particularly in a heterologous cell, masks its cortisol-binding 
activity and that its secretion is preceded by release from 
such a protein complex. 
A related issue is whether hCBG binds cortisol intracellu- 
larly; if so, cortisol binding might be required for secretion. 
The solubility properties of cortisol suggest that it is freely 
accessible to the lumenal spaces of the ER and Golgi; thus, 
binding could take place in these compartments. The secre- 
tion from hepatocytes of a related protein, retinol binding 
protein, has been shown to require retinol binding in the ER 
(30), and our preliminary results in the Sf9 system suggest 
that the presence of cortisol increases the secretion and/or 
stability of hCBG (unpublished data). Since Sf9 cells do not 
require cortisol for growth, they provide an excellent system 
for investigating the possible role of ligand binding in the 
biogenesis of this protein. 
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